BASEL, Switzerland — Medartis, an orthopaedic company with a manufacturing facility in Warsaw, reported total sales (based on the Swiss Franc) rise over a recent six-month period.

U.S. operations were listed as one of several key growth factors in the update.

Matthias Schupp, CEO of Medartis, said, “We delivered on our H1 commitments, giving us confidence in our outlook for the remainder of the year. My focus as CEO over the past nine months has been to strengthen our competitive positioning in the U.S. and LATAM, and to finalize partnerships with NeoOrtho and KeriMedical that will serve as significant growth catalysts beyond 2025.”

“We have also strengthened our R&D team to accelerate internal innovation. The cultural transformation is showing early positive signs – our U.S. team has regained confidence, demonstrating a shift in attitude and adopted a more focused approach, he said.

Medarti has a production facility in the Warsaw Technology Park just north of US 30.